AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04143516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor ablation (TA)
Description: Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
Study NCT04143516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
Study NCT01221129 — intervention group
Intervention type: OTHER
Intervention: Acclimation
Description: 11 mg Zn/day as a controlled intake level
Study NCT01221129 — intervention group
Intervention type: OTHER
Intervention: Dietary zinc depletion
Description: \< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
Study NCT01221129 — intervention group
Intervention type: OTHER
Intervention: Dietary zinc repletion
Description: 15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
Study NCT05124444 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: High throughput DNA and RNA sequencing
Description: High throughput DNA and RNA sequencing
Study NCT01203215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 print based physical activity interventions
Description: physical activity promotion
Study NCT01203215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 print based physical activity interventions
Description: physical activity promotion
Study NCT03882762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 200 μg tablet
Description: 200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
Study NCT04410731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy
Description: Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
Study NCT04200586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
Study NCT02645253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 inhalation powder (200 μg)
Description: 200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
Study NCT02645253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 inhalation powder (400 μg)
Description: Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
Study NCT02645253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 pressurized inhalation suspension (200 μg)
Description: 400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
Study NCT02645253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 placebo inhalation powder
Description: AZD7594 placebo inhalation powder via multi-dose DPI
Study NCT02645253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 placebo pressurized inhalation suspension
Description: AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
Study NCT03579394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retarded IDS (Interval Debulking Surgery)
Description: Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)
Study NCT03579394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IDS (Interval Debulking Surgery)
Description: Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)
Study NCT03681470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aczone Gel
Description: Aczone Gel 7.5%
Study NCT03053362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Observing change in cognition using THINC-it tool in patients with MDD.
Study NCT03053362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: THINC-it Tool
Description: Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Study NCT03053362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THINC-it Tool
Description: Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Study NCT00869193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Subjects will daily consume one capsule with grape seed extract for 8 weeks.
Study NCT00869193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose (placebo)
Description: Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
Study NCT03429556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin Serotype E
Description: Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
Study NCT03429556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
Study NCT00052715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Study NCT02864303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva samples
Description: saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
Study NCT02458976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL
Study NCT02496429 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BrownieForSymphony use
Description: Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
Study NCT03306121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF+CCRT
Description: Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
Study NCT03306121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT+ PF
Description: Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
Study NCT04984135 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
Study NCT03940105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Packout
Description: Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
Study NCT01855230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: ASM-024 b.i.d for 14 days
Study NCT01855230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo b.i.d. for 14 days
Study NCT03586804 — intervention group
Intervention type: OTHER
Intervention: dual task
Description: mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
Study NCT05041764 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: No INTERVENTION
Study NCT01095861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexTip ETT (Parker FlexTip/GlideScope FlexTip)
Description: FlexTip ETT used for endotracheal intubation
Study NCT01095861 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control - standard flexible ETT (Mallinckrodt)
Description: Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134
Study NCT01192932 — intervention group
Intervention type: RADIATION
Intervention: Chest CT scan
Description: Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm
Study NCT01791686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1135
Study NCT04286074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% resistance
Description: Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
Study NCT04286074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% resistance
Description: Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
Study NCT00367471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
Study NCT03243786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle- Supportive Care
Description: The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
Study NCT05294783 — intervention group
Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: ACL reconstruction is a standard surgery for ACL injured patients
Study NCT01452789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Description: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
Study NCT01452789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Description: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
Study NCT01419925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two Multimeric-001 administrations followed by TIV
Description: Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
Study NCT01419925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One administration of Multimeric-001 followed by TIV
Description: One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
Study NCT01419925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One administration of adjuvanted M-001 followed by TIV
Description: One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
Study NCT01419925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: One administration of placebo followed by TIV
Description: One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
Study NCT00949143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rear axle position
Description: Wheelchair axle position located as far towards the rear of the wheelchair as possible.
Study NCT00949143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: forward axle position
Description: Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
Study NCT02006212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period
Study NCT02833181 — intervention group
Intervention type: DEVICE
Intervention: BIS monitor
Description: Monitoring circadian variation of EEG
Study NCT06502301 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional study
Description: This is not intervention study.
Study NCT02826694 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Well infant, whole exome sequencing
Description: Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
Study NCT02826694 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Diagnosed, whole exome sequencing
Description: In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
Study NCT04419350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
Study NCT01559285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% ropivacaine concentration
Description: 0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study NCT01559285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375% ropivacaine concentration
Description: 0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study NCT01559285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine concentration
Description: 0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
Description: Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
Description: Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
Description: Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance
Description: Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance
Description: Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
Study NCT01554852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
Description: High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
Study NCT03722030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength-Training
Description: 2 sessions per week (20-40 min), home-based resistance training